Logistical study to deal with the practical issues of how the product fits into the current Danish national CRC screening program
NAMUR, Belgium, March 2, 2017 /PRNewswire/ -- Volition (NYSE MKT: VNRX) announced today that it has begun a two-phase logistical study of the Company's novel Nu.QTM Colorectal Cancer Screening Triage blood test. The study is in collaboration with Hvidovre Hospital and The Danish Research Group on Early Detection of Colorectal Cancer; both phases are expected to be completed within 6 months.
The first phase of the study starts today in the Capital Region of Denmark and involves three centres and up to 250 subjects. The aim of the study is to evaluate the logistics in collecting and processing blood samples at a local screening centre and subsequently shipping the samples to a central laboratory in Denmark to run the Nu.QTM analysis. This phase is expected to be completed within 2 months.
The second phase of the study is due to start after Ethical Approval and will involve five centres and up to 500 subjects. Specifically, this phase will assess the time taken between blood collection, analysis and results. When added to the existing clinical data previously announced, this logistics study aims to complete the information needed to add our test to the national screening program.
Morten Rasmussen MD. Ph.D., head of the colorectal screening program in the Capital Region of Denmark, commented "We have been impressed with the preliminary clinical data of the Nu.QTM Colorectal Cancer Screening Triage Test and the potential to reduce unnecessary colonoscopies. Many healthcare systems in Europe, including Denmark, are struggling to meet the increased colonoscopy demand that has come from the implementation of fecal-based colorectal cancer screening programs. Before introducing any such test into the Danish National Screening program, we need to determine the very practical logistics of putting into practice Volition's Nu.QTM Triage Test to ensure a smooth, patient-friendly, and efficient implementation of our screening programme."
Volition's CEO Cameron Reynolds added: "This is extremely important news for Volition in the implementation of our commercialisation strategy for our first product. Denmark has one of the most advanced healthcare systems in the world and is viewed by many as strong innovators. We have had a long, mutually beneficial relationship with our collaborators in Denmark and are very pleased that this logistics study will be undertaken to answer key issues to make sure any potential roll out nationally would be smooth. We also envisage this study will assist other countries in assessing the implementation of the Nu.QTM Triage Test within their National Screening Programs."
About Nu.QTM Colorectal Cancer Screening Triage Test
There is currently a significant strain on colonoscopy capacity which can lead to longer waiting times in European healthcare systems due to the expansion of colorectal cancer screening programs. Therefore, there is a pressing need to prioritise the colonoscopy referrals for those at high risk. Volition aims to meet this need with its new Nu.QTM Colorectal Cancer Screening Triage Test.
Having received a CE mark for the Nu.QTM Colorectal Cancer Screening Triage Test in December 2016, Volition plans to launch the test for the European Union screening population.
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.
As cancer screening programs become more and more widespread, our products can help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, join us on our upcoming Earnings Call, visit Volition's website (http://www.volitionrx.com) or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Day, Volition
+44 (0)7557 774620
Scott Powell, Volition
+1 (646) 650 1351
Tirth Patel, Edison Advisors
+1 (646) 653 7035
Rachel Carroll, Edison Advisors
+44 (0)20 3077 5711
Sarah Roberts, Vane Percy & Roberts
+44 (0)1737 821 890
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/a-logistics-and-pathway-design-study-for-volitions-ce-marked-nuqtm-triage-test-has-been-commenced-in-the-capital-region-of-denmark-300416808.html
SOURCE VolitionRx Ltd